Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration

Luis Miguel Blanco-Colio, Jose Luis Martín-Ventura, Eduardo de Teresa, C. Farsang, Allan Gaw, GianFranco Gensini, Lawrence A. Leiter, Anatoly Langer, Pierre Martineau, Jesús Egido

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background: Plasma levels of soluble intercellular adhesion molecule 1 (sICAM-1) and monocyte chemoattractant protein 1 (sMCP-1) are associated with increased risk for future coronary events. However, the effect of statins on these inflammatory markers has hardly been studied. We analyzed whether treatment with the different doses of atorvastatin affects sICAM-1 and sMCP-1 plasma levels in subjects at high cardiovascular risk. Methods: Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration was a 12-week, prospective, multicenter, open-label trial that enrolled a total of 2117 subjects with coronary heart disease (CHD), CHD equivalent (defined as diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects with low-density-lipoprotein cholesterol between 100 and 220 mg/dL (2.6-5.7 mmol/L) and triglycerides

Original languageEnglish
Pages (from-to)881-888
Number of pages8
JournalAmerican Heart Journal
Volume153
Issue number5
DOIs
Publication statusPublished - May 2007

Fingerprint

Intercellular Adhesion Molecule-1
Coronary Disease
Chemokine CCL2
Cholesterol
Cerebrovascular Disorders
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Peripheral Vascular Diseases
LDL Cholesterol
Triglycerides
Atorvastatin Calcium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study : A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. / Blanco-Colio, Luis Miguel; Martín-Ventura, Jose Luis; de Teresa, Eduardo; Farsang, C.; Gaw, Allan; Gensini, GianFranco; Leiter, Lawrence A.; Langer, Anatoly; Martineau, Pierre; Egido, Jesús.

In: American Heart Journal, Vol. 153, No. 5, 05.2007, p. 881-888.

Research output: Contribution to journalArticle

Blanco-Colio, Luis Miguel ; Martín-Ventura, Jose Luis ; de Teresa, Eduardo ; Farsang, C. ; Gaw, Allan ; Gensini, GianFranco ; Leiter, Lawrence A. ; Langer, Anatoly ; Martineau, Pierre ; Egido, Jesús. / Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study : A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. In: American Heart Journal. 2007 ; Vol. 153, No. 5. pp. 881-888.
@article{f5d78eabaa8b4a5fb34fe13a95c9f543,
title = "Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration",
abstract = "Background: Plasma levels of soluble intercellular adhesion molecule 1 (sICAM-1) and monocyte chemoattractant protein 1 (sMCP-1) are associated with increased risk for future coronary events. However, the effect of statins on these inflammatory markers has hardly been studied. We analyzed whether treatment with the different doses of atorvastatin affects sICAM-1 and sMCP-1 plasma levels in subjects at high cardiovascular risk. Methods: Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration was a 12-week, prospective, multicenter, open-label trial that enrolled a total of 2117 subjects with coronary heart disease (CHD), CHD equivalent (defined as diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20{\%}. Subjects with low-density-lipoprotein cholesterol between 100 and 220 mg/dL (2.6-5.7 mmol/L) and triglycerides",
author = "Blanco-Colio, {Luis Miguel} and Mart{\'i}n-Ventura, {Jose Luis} and {de Teresa}, Eduardo and C. Farsang and Allan Gaw and GianFranco Gensini and Leiter, {Lawrence A.} and Anatoly Langer and Pierre Martineau and Jes{\'u}s Egido",
year = "2007",
month = "5",
doi = "10.1016/j.ahj.2007.02.029",
language = "English",
volume = "153",
pages = "881--888",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study

T2 - A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration

AU - Blanco-Colio, Luis Miguel

AU - Martín-Ventura, Jose Luis

AU - de Teresa, Eduardo

AU - Farsang, C.

AU - Gaw, Allan

AU - Gensini, GianFranco

AU - Leiter, Lawrence A.

AU - Langer, Anatoly

AU - Martineau, Pierre

AU - Egido, Jesús

PY - 2007/5

Y1 - 2007/5

N2 - Background: Plasma levels of soluble intercellular adhesion molecule 1 (sICAM-1) and monocyte chemoattractant protein 1 (sMCP-1) are associated with increased risk for future coronary events. However, the effect of statins on these inflammatory markers has hardly been studied. We analyzed whether treatment with the different doses of atorvastatin affects sICAM-1 and sMCP-1 plasma levels in subjects at high cardiovascular risk. Methods: Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration was a 12-week, prospective, multicenter, open-label trial that enrolled a total of 2117 subjects with coronary heart disease (CHD), CHD equivalent (defined as diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects with low-density-lipoprotein cholesterol between 100 and 220 mg/dL (2.6-5.7 mmol/L) and triglycerides

AB - Background: Plasma levels of soluble intercellular adhesion molecule 1 (sICAM-1) and monocyte chemoattractant protein 1 (sMCP-1) are associated with increased risk for future coronary events. However, the effect of statins on these inflammatory markers has hardly been studied. We analyzed whether treatment with the different doses of atorvastatin affects sICAM-1 and sMCP-1 plasma levels in subjects at high cardiovascular risk. Methods: Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration was a 12-week, prospective, multicenter, open-label trial that enrolled a total of 2117 subjects with coronary heart disease (CHD), CHD equivalent (defined as diabetes, peripheral vascular disease, or cerebrovascular disease), or a 10-year CHD risk >20%. Subjects with low-density-lipoprotein cholesterol between 100 and 220 mg/dL (2.6-5.7 mmol/L) and triglycerides

UR - http://www.scopus.com/inward/record.url?scp=34247166151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247166151&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2007.02.029

DO - 10.1016/j.ahj.2007.02.029

M3 - Article

C2 - 17452168

AN - SCOPUS:34247166151

VL - 153

SP - 881

EP - 888

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -